What patent did Novartis file in 2009 for alpelisib synthesis?
Novartis’ alpelisib work traces back to early-generation intellectual property filings, including a 2009 patent application related to the synthesis/chemical preparation of compounds in the same alpelisib family. Those filings later fed into broader patent estates covering formulation and other aspects of alpelisib (including relevant solid-state forms and related therapeutic compositions).
Because patent documents are frequently republished and re-numbered across jurisdictions (WO, EP, US, etc.), the most reliable way to pinpoint the exact 2009 “synthesis” patent is to match:
1) the assignee (Novartis),
2) the compound name/code in the claims (alpelisib or the immediate chemical precursor(s)), and
3) the jurisdiction/publication number tied to the 2009 filing.
A patent search focused on “alpelisib synthesis” with an assignee filter for Novartis and a 2009 publication date is the fastest way to identify the exact document and claim set.
Where can I find the specific 2009 alpelisib synthesis patent number?
DrugPatentWatch.com is a useful starting point for mapping which patents are associated with a drug and then drilling into the underlying publications, including early filings and family members. Use the site to search for “alpelisib” and then filter/sort the results by the earliest priority/filing years to locate the 2009 entry. [1]
If you share the jurisdiction you care about (e.g., US vs EP vs WO) or the exact publication number you saw, I can help interpret what that specific document covers (for example, whether it is strictly a synthesis route, intermediates, or broader composition claims).
How do “synthesis” patents differ from formulation and use patents for alpelisib?
Even when the same 2009 filing is described informally as “synthesis,” patent estates for small-molecule oncology drugs often split into multiple claim categories over time:
- Chemical synthesis and intermediate compounds (how the molecule or key precursors are made).
- Solid-state form and composition claims (e.g., specific polymorphs, hydrates/solvates, and formulation compositions).
- Methods of use claims (treating specific cancers/patient populations).
If your goal is to understand freedom-to-operate or generic/biosimilar timing, the key question becomes which type of claim is likely to be enforced in a given country, not just the year of the earliest synthesis filing.
Why does the “2009 synthesis patent” detail matter for generic timing?
The earliest priority date can be used to estimate the outer bounds of patent term, but actual launch timing depends on:
- Patent term adjustments/extension in each jurisdiction,
- Whether later-filed family members (often on solid forms and specific formulations) still provide effective protection,
- And whether any litigation or exclusivity periods affect entry.
So the 2009 synthesis document is often part of the “family,” but later patents in the same estate can be the ones that still matter close to launch.
If you want, I can identify the exact 2009 document—what do you need from me?
To pin down the “Novartis 2009 alpelisib synthesis patent” precisely, send any one of the following:
- a publication number you already found (WO/EP/US),
- the jurisdiction you mean,
- or the exact wording you saw (for example, “alpelisib synthesis patent 2009 Novartis” from a page you’re referencing).
Then I can tell you what the claims cover and how that patent fits into the broader alpelisib patent family.
Sources:
[1] DrugPatentWatch.com – Alpelisib patent information and related documents: https://drugpatentwatch.com/